Corbus receives approval for open-label extension of Resunab Phase 2 trial

Corbus Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for initiating a 12-month open-label extension study of the in-progress Phase 2 clinical trial of Resunab to treat diffuse cutaneous systemic sclerosis (scler…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news